The estimated Net Worth of Partners 2007, L.P.Presidio... is at least $842 Thousand dollars as of 18 April 2016. Partners Presidio owns over 20,367 units of Neos Therapeutics Inc stock worth over $45,998 and over the last 9 years Partners sold NEOS stock worth over $796,275.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Partners Presidio NEOS stock SEC Form 4 insiders trading
Partners has made over 2 trades of the Neos Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Partners sold 20,367 units of NEOS stock worth $203,263 on 18 April 2016.
The largest trade Partners's ever made was selling 57,968 units of Neos Therapeutics Inc stock on 13 April 2016 worth over $593,013. On average, Partners trades about 26,112 units every 2 days since 2015. As of 18 April 2016 Partners still owns at least 39,998 units of Neos Therapeutics Inc stock.
You can see the complete history of Partners Presidio stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Neos Therapeutics Inc
Over the last 9 years, insiders at Neos Therapeutics Inc have traded over $796,275 worth of Neos Therapeutics Inc stock and bought 558,630 units worth $7,201,055 . The most active insiders traders include Jack W Schuler, James E Deerfield Mgmt L.P...., and Bryant Fong. On average, Neos Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $42,698. The most recent stock trade was executed by Richard I Eisenstadt on 12 December 2018, trading 5,000 units of NEOS stock currently worth $10,800.
What does Neos Therapeutics Inc's logo look like?
Complete history of Partners Presidio stock trades at Neos Therapeutics Inc
Neos Therapeutics Inc executives and stock owners
Neos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Gerald McLaughlin,
President, Chief Executive Officer, Director -
Richard Eisenstadt,
Chief Financial Officer, Treasurer -
John Limongelli,
Senior Vice President, General Counsel and Corporate Secretary -
Alan Heller,
Independent Chairman of the Board -
Linda Szyper,
Independent Director -
John Schmid,
Independent Director -
Gregory Robitaille,
Independent Director -
Bryant Fong,
Independent Director -
James Robinson,
Independent Director -
Beth Hecht,
Independent Director -
Vipin K Garg,
President, CEO & Director -
Juergen Martens,
Chief Tech/Operations Officer -
Thomas P Mc Donnell,
Chief Commercial Officer -
Paul R Edick,
Director -
Partners 2007, L.P.Presidio...,
-
Dorothy Engelking,
VP of Regulatory Affairs -
Mark Tengler,
Chief Technology Officer -
Ralph Essex Capital Corp Ia...,
-
Andrew G Delaware Street Ca...,
-
Jack W Schuler,
10% owner -
Venture Assoicates Ii Llcbu...,
-
James E Deerfield Mgmt L.P....,